Bioiasis Jsc Plans an SPO

Bioiasis Jsc Plans an SPO

At its meeting today the Financial Supervision Commission approved Bioiasis Jsc's prospectus for a secondary public offering of shares.

The issue's value stands at 200,000 leva allocated in as many common shares with a face value of 1 lev representing the company's capital.

Bioiasis's Board of Directors includes Georgios Kisas (chair and executive director), Dimitrios Sotiropulos, and Dimitrios Dumbalis. Main shareholders are Georgios Kisas (70%) and Dimitrios Sotiropoulos (30%).

The company's core activity is purchase and resale of goods, commercial representation and intermediation, export and import, wholesale of medical products, disinfectants, hygiene products, cosmetics etc.

The company is a distributor of products in the filed of neurosurgery, invasive cardiology, orthopaedy, rheumatology, intensive care.

Bioiasis Jsc sell its products directly to hospitals, pharmacies and consumers and participates in medical tenders.

Facebook Коментари

Добави коментар

Екипът на Ви благодари, че използвате кирилица за вашите коментари.
В случай, че коментарът Ви съдържа нецензурни квалификации и лични нападки или обиди на расова, сексуална, етническа или верска основа, той ще бъде изтрит от модератора на сайта.

Абонирайте се за електронния
информационен бюлетин на